Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
125Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-158.35M | $-1.94 |
| 2024 | $0.00 | $-168.38M | $-2.00 |
| 2023 | $0.00 | $-135.96M | $-1.63 |
| 2022 | $0.00 | $-115.91M | $-1.39 |
| 2021 | $351.37M | $121.19M | $1.46 |
Social Signal Score
Earnings
Wed, Nov 11(in 3 months)
Consensus estimate $-0.51 per share
Typical surprise +4.3% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.41 vs $-0.56beat
- Tue, May 12$-0.57 vs $-0.60beat
- Thu, Mar 5$-0.57 vs $-0.49miss
- Wed, Nov 12$-0.53 vs $-0.46miss
- Thu, Aug 7$-0.44 vs $-0.46beat
- Mon, May 12$-0.40 vs $-0.56beat
Estimates and results for AVIR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
AVIRhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (2)
- Newsseekingalpha.com·2d ago·Positive
Atea Pharmaceuticals, Inc. (AVIR) Q2 2026 Earnings Call Transcript Atea Pharmaceuticals, Inc. (AVIR) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·2d ago·Positive
Atea Pharmaceuticals Q2 Earnings Call Highlights Atea Pharmaceuticals NASDAQ: AVIR reported positive top-line results from its Phase III C-BEYOND trial of bemnifosbuvir/ruzasvir for chronic hepatitis C virus, saying the study met its primary and secondary endpoints against the standard-of-care regimen sofosbuvir/velpatasvir, marketed as Epclusa.
View source ↗